CytomX Therapeutics Total Liabilities 2014-2022 | CTMX
CytomX Therapeutics total liabilities from 2014 to 2022. Total liabilities can be defined as the total value of all possible claims against the corporation.
CytomX Therapeutics Annual Total Liabilities
(Millions of US $) |
| 2021 |
$250 |
| 2020 |
$309 |
| 2019 |
$290 |
| 2018 |
$326 |
| 2017 |
$328 |
| 2016 |
$121 |
| 2015 |
$71 |
| 2014 |
$75 |
| 2013 |
$14 |
CytomX Therapeutics Quarterly Total Liabilities
(Millions of US $) |
| 2022-09-30 |
$198 |
| 2022-06-30 |
$211 |
| 2022-03-31 |
$229 |
| 2021-12-31 |
$250 |
| 2021-09-30 |
$260 |
| 2021-06-30 |
$271 |
| 2021-03-31 |
$288 |
| 2020-12-31 |
$309 |
| 2020-09-30 |
$327 |
| 2020-06-30 |
$344 |
| 2020-03-31 |
$367 |
| 2019-12-31 |
$290 |
| 2019-09-30 |
$290 |
| 2019-06-30 |
$304 |
| 2019-03-31 |
$322 |
| 2018-12-31 |
$326 |
| 2018-09-30 |
$325 |
| 2018-06-30 |
$336 |
| 2018-03-31 |
$327 |
| 2017-12-31 |
$328 |
| 2017-09-30 |
$342 |
| 2017-06-30 |
$300 |
| 2017-03-31 |
$104 |
| 2016-12-31 |
$121 |
| 2016-09-30 |
$103 |
| 2016-06-30 |
$106 |
| 2016-03-31 |
$79 |
| 2015-12-31 |
$71 |
| 2015-09-30 |
$72 |
| 2015-06-30 |
$0 |
| 2015-03-31 |
$0 |
| 2014-12-31 |
|
| 2014-09-30 |
$0 |
| 2013-12-31 |
$14 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.115B |
$0.070B |
|
CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.
|
